BioSpace News Archive

Black Diamond Therapeutics, Inc., a precision oncology medicine company pioneering the discovery and development of small molecule, MasterKey therapies, announced the presentation of preclinical data on BDTX-189 and BDTX-1535 at the American Association for Cancer Research Annual Meeting, taking place April 9-14, 2021.

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced the availability of three poster presentations at the American Association for Cancer Research Annual Meeting.

CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced preclinical data from the Company’s allogeneic chimeric antigen receptor T cell program at the American Association for Cancer Research Annual Meeting 2021.

ESSA Pharma Inc., a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, presented new preclinical data on ESSA’s lead product candidate, EPI-7386, at the 2021 American Association of Cancer Research Annual Meeting, which is taking place virtually April 10-15, 2021.

OncoMyx’s multi-armed myxoma virotherapy upregulates genes associated with immune response and shows modulation of the immune response to favor anti-tumor immunity

SQZ enhanced APCs (eAPCs) demonstrated ability to meaningfully increase CD8 T cell response through incorporation of costimulatory molecules and cytokine signaling

Nearly a quarter of patients who received Opdivo plus chemotherapy showed no evidence of cancer cells in tissue removed during surgery vs. 2.2% of patients who received chemotherapy alone

ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that a poster highlighting preclinical data for its novel ADAM9-targeting ADC, IMGC936, which is being investigated in multiple solid tumor types, is being presented at the American Association of Cancer Research Virtual Annual Meeting April 10-15, 2021.

Gracell Biotechnologies Inc. presented updated long-term follow-up data on their TruUCAR-enabled allogeneic product candidate GC027 for the treatment of adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia in an e-poster presentation at the 2021 American Association for Cancer Research Annual Meeting on April 10.

JBI-778, a brain penetrant PRMT5 inhibitor demonstrated significant tumor growth inhibition in glioblastoma in addition to its activity against a number of other cancers